Opioid agonist / antagonist combinations
AssigneePurdue Pharma L.P.
InventorsRobert F. Kaiko, Robert D. Colucci
Life of this patent
Estimating the term…
Abstract
The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
Claims21
A solid oral dosage form, comprising a combination of an opioid agonist and naltrexone or a pharmaceutically acceptable salt thereof;
- wherein the combination is orally therapeutically effective for the treatment of pain and is selected from the group consisting of:
- naltrexone or a pharmaceutically acceptable salt thereof and hydrocodone or a pharmaceutically acceptable salt thereof, in a weight ratio of from about 0.03:1 to about 0.27:1;
- naltrexone or a pharmaceutically acceptable salt thereof and oxycodone or a pharmaceutically acceptable salt thereof, in a weight ratio of from about 0.037:1 to about 0.296:1;
- naltrexone or a pharmaceutically acceptable salt thereof and hydromorphone or a pharmaceutically acceptable salt thereof, in a weight ratio of from about 0.148:1 to about 1.185:1;
- naltrexone or a pharmaceutically acceptable salt thereof and levorphanol or a pharmaceutically acceptable salt thereof, in a weight ratio of from about 0.278:1 to about 2.222:1;
- naltrexone or a pharmaceutically acceptable salt thereof and morphine or a pharmaceutically acceptable salt thereof, in a weight ratio of from about 0.018:1 to about 0.148:1.
Dependencies are inferred from the claim text.